Morgan Stanley
EIGR

Morgan Stanley’s Eiger BioPharmaceuticals, Inc. EIGR Stock Holding History

Morgan Stanley’s Portfolio EIGR Stock Details EIGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-366
Closed -$1.83K – 8069
2024
Q1 		$1.83K Sell
366
-555
-60% -$3.45K ﹤0.01% 7086
2023
Q4 		$6.2K Sell
921
-62
-6% -$545 ﹤0.01% 6951
2023
Q3 		$9K Sell
983
-1,040
-51% -$20.9K ﹤0.01% 6764
2023
Q2 		$42.7K Sell
2,023
-424
-17% -$13.1K ﹤0.01% 6272
2023
Q1 		$65.8K Sell
2,447
-25,186
-91% -$1.17M ﹤0.01% 6177
2022
Q4 		$978K Buy
27,633
+11,240
+69% +$1.35M ﹤0.01% 4885
2022
Q3 		$3.7M Sell
16,393
-13,514
-45% -$3.32M ﹤0.01% 3941
2022
Q2 		$5.65M Sell
29,907
-17,502
-37% -$3.53M ﹤0.01% 3655
2022
Q1 		$11.8M Buy
47,409
+33,404
+239% +$5.28M ﹤0.01% 2714
2021
Q4 		$2.18M Buy
14,005
+10,366
+285% +$2M ﹤0.01% 4519
2021
Q3 		$730K Sell
3,639
-211
-5% -$50.2K ﹤0.01% 5268
2021
Q2 		$985K Buy
3,850
+2,029
+111% +$506K ﹤0.01% 5086
2021
Q1 		$483K Buy
1,821
+1,025
+129% +$323K ﹤0.01% 5173
2020
Q4 		$293K Buy
796
+629
+377% +$180K ﹤0.01% 5385
2020
Q3 		$41K Sell
167
-750
-82% -$233K ﹤0.01% 5795
2020
Q2 		$264K Buy
917
+279
+44% +$82.2K ﹤0.01% 4945
2020
Q1 		$130K Sell
638
-547
-46% -$174K ﹤0.01% 5077
2019
Q4 		$530K Buy
1,185
+839
+242% +$298K ﹤0.01% 4895
2019
Q3 		$107K Sell
346
-160
-32% -$52K ﹤0.01% 5427
2019
Q2 		$161K Sell
506
-1,562
-76% -$541K ﹤0.01% 5117
2019
Q1 		$867K Buy
2,068
+305
+17% +$122K ﹤0.01% 4213
2018
Q4 		$538K Buy
1,763
+1,410
+399% +$456K ﹤0.01% 4739
2018
Q3 		$127K Sell
353
-594
-63% -$203K ﹤0.01% 5616
2018
Q2 		$347K Sell
947
-125
-12% -$44.5K ﹤0.01% 5303
2018
Q1 		$316K Buy
1,072
+651
+155% +$192K ﹤0.01% 5256
2017
Q4 		$176K Sell
421
-83
-16% -$29.7K ﹤0.01% 5458
2017
Q3 		$166K Sell
504
-19
-4% -$5.18K ﹤0.01% 5426
2017
Q2 		$124K Buy
523
+340
+186% +$77.3K ﹤0.01% 5552
2017
Q1 		$63K Sell
183
-221
-55% -$76.1K ﹤0.01% 5761
2016
Q4 		$141K Buy
404
+375
+1,293% +$137K ﹤0.01% 5466
2016
Q3 		$11K Buy
29
+26
+867% +$13.3K ﹤0.01% 6093
2016
Q2 		$2K Sell
3
-30
-91% -$18.2K ﹤0.01% 6374
2016
Q1 		$17K Buy
33
+11
+50% +$5.48K ﹤0.01% 5976
2015
Q4 		$15K Sell
22
-24
-52% -$13.6K ﹤0.01% 6128
2015
Q3 		$22K Sell
46
-92
-67% -$48.8K ﹤0.01% 6025
2015
Q2 		$77K Sell
138
-97
-41% -$268K ﹤0.01% 5715
2015
Q1 		$2M Buy
235
+234
+23,400% +$2.05M ﹤0.01% 3589
2014
Q4 		$7K Buy
+1
New +$5.8K ﹤0.01% 6277
2014
Q3 		– Sell
-5
Closed -$38K – 6684
2014
Q2 		$38K Sell
5
-50
-91% -$250K ﹤0.01% 5850
2014
Q1 		$294K Buy
+55
New +$260K ﹤0.01% 4902

Other funds holding EIGR

PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Morgan Stanley's EIGR Position: Q2 2024 in Review

Morgan Stanley sold out of Eiger BioPharmaceuticals, Inc. (EIGR) in Q2 2024, closing a stake of 366 shares — an estimated $1.83K sold.

Morgan Stanley first reported a position in EIGR in Q1 2014 and held it in 40 quarters. The position peaked at $11.8M in Q1 2022. 2 funds tracked by Wall St. Rank hold EIGR as of Q2 2024.

  • Morgan Stanley reported no remaining Eiger BioPharmaceuticals, Inc. position as of Q2 2024 after selling out during the quarter.
  • Morgan Stanley sold 366 Eiger BioPharmaceuticals, Inc. shares in Q2 2024, an estimated $1.83K.
  • Morgan Stanley first reported a position in Eiger BioPharmaceuticals, Inc. in Q1 2014 and held it in 40 quarters.
  • Morgan Stanley's Eiger BioPharmaceuticals, Inc. position peaked at $11.8M in Q1 2022.
  • 2 funds tracked by Wall St. Rank held Eiger BioPharmaceuticals, Inc. as of Q2 2024.

Based on Morgan Stanley's 13F filing for Q2 2024, filed 14 Aug 2024.